Literature DB >> 3199170

International criteria for diagnosis, staging, and response to treatment in patients with neuroblastoma.

G M Brodeur1, R C Seeger, A Barrett, F Berthold, R P Castleberry, G D'Angio, B De Bernardi, A E Evans, M Favrot, A I Freeman.   

Abstract

Neuroblastoma is one of the most common tumors in childhood. However, it often has been difficult to compare clinical and laboratory studies of this disease due to a lack of uniform criteria for diagnosis, staging, and response. An international group of conferees addressed each of these issues and reached a consensus. Specific criteria for making a diagnosis of neuroblastoma are defined. A new neuroblastoma staging system is proposed that takes into account the most important elements of current but incompatible systems. Finally, criteria for response to treatment are standardized. The criteria proposed herein represent an international consensus of essentially every major pediatric oncology group or organization in the United States, Europe, and Japan. The staging system should be referred to as the International Neuroblastoma Staging System, and the response criteria as the International Neuroblastoma Response Criteria. Implementation of these criteria will greatly facilitate the comparison of clinical and laboratory studies by different groups and countries. Furthermore, these criteria should serve as a foundation on which future modifications or improvements can be based.

Entities:  

Mesh:

Year:  1988        PMID: 3199170     DOI: 10.1200/JCO.1988.6.12.1874

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  99 in total

1.  Neuroblastoma with atypical metastases to cardiac and skeletal muscles: MRI features.

Authors:  Ricardo Faingold; Paul S Babyn; Shi-Joon Yoo; Anne I Dipchand; Sheila Weitzman
Journal:  Pediatr Radiol       Date:  2003-05-24

Review 2.  New aspects of neuroblastoma treatment: ASPHO 2011 symposium review.

Authors:  Peter E Zage; Chrystal U Louis; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2012-02-29       Impact factor: 3.167

3.  Urine catecholamine levels as diagnostic markers for neuroblastoma in a defined population: implications for ophthalmic practice.

Authors:  S J Smith; N N Diehl; B D Smith; B G Mohney
Journal:  Eye (Lond)       Date:  2010-09-24       Impact factor: 3.775

4.  Association between end-induction response according to the revised International Neuroblastoma Response Criteria (INRC) and outcome in high-risk neuroblastoma patients.

Authors:  Erin K Barr; Kathryn Laurie; Kristen Wroblewski; Mark A Applebaum; Susan L Cohn
Journal:  Pediatr Blood Cancer       Date:  2020-07-25       Impact factor: 3.167

Review 5.  [Neuroblastoma].

Authors:  Victoria Castel; Adela Cañete; Rosa Noguera; Samuel Navarro; Silvestre Oltra
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

Review 6.  Spontaneous regression of neuroblastoma.

Authors:  Garrett M Brodeur
Journal:  Cell Tissue Res       Date:  2018-01-05       Impact factor: 5.249

7.  Detection of bone marrow metastases in neuroblastoma using a short term tissue culture technique.

Authors:  J A Adams; A M Kelsey; T F Carr; R F Stevens; P Morris-Jones
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

8.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells.

Authors:  C Hirschmann-Jax; A E Foster; G G Wulf; J G Nuchtern; T W Jax; U Gobel; M A Goodell; M K Brenner
Journal:  Proc Natl Acad Sci U S A       Date:  2004-09-20       Impact factor: 11.205

9.  Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors.

Authors:  U M Moll; M LaQuaglia; J Bénard; G Riou
Journal:  Proc Natl Acad Sci U S A       Date:  1995-05-09       Impact factor: 11.205

10.  MAGE-A1 expression is associated with good prognosis in neuroblastoma tumors.

Authors:  Elena Grau; Silvestre Oltra; Francisco Martínez; Carmen Orellana; Adela Cañete; Jose María Fernández; Miguel Hernández-Martí; Victoria Castel
Journal:  J Cancer Res Clin Oncol       Date:  2008-09-27       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.